Home Featured Page 171

Featured

Latest

Psychedelic Medicine at the Edge of Science and Spirit

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin...

Manvir Singh: Shamanism, the Timeless Religion

2025 Year in Review: Future(s) & Open Questions (Video)

2025 Year in Review: 10 Standout Stories in Psychedelics

PT323 – Dr. Reid Robison & Steve Thayer, Ph.D. – Ketamine-Assisted...

Psychedelic Bulletin #104 – Mydecine CEO Downplays Insider Activity; UC Davis...

PT322 – Kimberly Juroviesky, Capt, USAF, Retired – Ketamine and...

Conflicting States of Consciousness: Exploring Psilocin and Sleep

Oregon, Measure 109, and Religious Freedom: The Final Vote

PT321 – Lyle Maxson – Virtual Reality, Biofeedback, and Digital Therapeutics:...

Psychedelic Bulletin #103 – MAPS Phase 3 Trial On Schedule;...

PT320 – Anne Philippi – The New Health Club, Intergenerational Trauma,...

PT319 – Kole – Activism and Trust: A Cautionary Tale From...

Psychedelic Medicine at the Edge of Science and Spirit

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts...

Manvir Singh: Shamanism, the Timeless Religion

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Medicine at the Edge of Science and Spirit

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin...

Manvir Singh: Shamanism, the Timeless Religion

2025 Year in Review: Future(s) & Open Questions (Video)

2025 Year in Review: 10 Standout Stories in Psychedelics

PT323 – Dr. Reid Robison & Steve Thayer, Ph.D. – Ketamine-Assisted...

Psychedelic Bulletin #104 – Mydecine CEO Downplays Insider Activity; UC Davis...

PT322 – Kimberly Juroviesky, Capt, USAF, Retired – Ketamine and...

Conflicting States of Consciousness: Exploring Psilocin and Sleep

Oregon, Measure 109, and Religious Freedom: The Final Vote

PT321 – Lyle Maxson – Virtual Reality, Biofeedback, and Digital Therapeutics:...

Psychedelic Bulletin #103 – MAPS Phase 3 Trial On Schedule;...

PT320 – Anne Philippi – The New Health Club, Intergenerational Trauma,...

PT319 – Kole – Activism and Trust: A Cautionary Tale From...

DO-Why? The Story of DOI

EDITOR PICKS

Psychedelic Medicine at the Edge of Science and Spirit

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts...

Manvir Singh: Shamanism, the Timeless Religion

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY